September 8, 2020 06:14 PM EDTUpdated September 9, 06:55 AM
R&D
Coronavirus

An­a­lysts as­sess fall­out af­ter As­traZeneca halts PhI­II Covid-19 vac­cine dos­ing to probe a pos­si­ble se­ri­ous ad­verse event

John Carroll

Editor & Founder

In­ves­ti­ga­tors at As­traZeneca have or­dered a halt to dos­ing their close­ly-watched Covid-19 vac­cine in or­der to probe a po­ten­tial­ly se­vere ad­verse event — re­port­ed­ly in­volv­ing in­flam­ma­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times